Truist Securities Reiterates Buy Rating on Insmed (INSM) as 'Preliminary Arikayce FY2024 Sales Exceed Guidance'
Tweet Send to a Friend
Truist Securities analyst Nicole Germino reiterated a Buy rating and $105.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
